Pilot study demonstrates improved dyspnea and exercise tolerance in fibrotic interstitial lung disease with nasal high-flow oxygen therapy, suggesting O2 supplementation benefits.
We tested the respective effect of high-flow and supplemental O₂ from nasal high-flow O₂ therapy (NHFO₂) on dyspnea and exercise tolerance in fibrotic interstitial lung disease. Supplemental O₂ and NHFO₂ (but not high-flow) provided improvements in these outcomes at "iso-O₂ saturation" due to reduced ventilatory requirements. Physiological benefits derived from O₂ supplementation are thus likely primary drivers of dyspnea relief and improved exercise tolerance on NHFO₂ (vs air) in these patients.
No takes yet. Share an insight, caveat, or question.
Thivent et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: